Estudio de seguimiento a largo plazo para pacientes tratados con tratamientos de linfocitos T-CAR de Galapagos
ESTADO CLÍNICO
Reclutando
FASE/S DEL ENSAYO
Fase III
PATOLOGÍA
Leucemia linfática crónica y otros SLPC, Leucemia mieloide aguda, Linfoma Hodgkin, Linfoma no Hodgkin, Mieloma Múltiple y otras gammapatías, Leucemia mieloide crónica, Linfoma, Leucemia
FECHA DE APERTURA
Junio, 2024
FECHA DE CIERRE
,
CRITERIOS DE INCLUSIÓN
Subject must sign and date the ICF as approved by the Independent Ethics Committee (IEC)/Institutional Review Board (IRB), prior to any study-related procedures.
Subjects has been treated with a GLPG CAR T-cell therapy in a clinical trial or Managed Access Program.
Subjects has been treated with a GLPG CAR T-cell therapy in a clinical trial or Managed Access Program.
CRITERIOS DE EXCLUSIÓN
There are no exclusion criteria for this study.
DESCRIPCIÓN
To evaluate the long-term safety of GLPG CAR T cell products for up to 15 years post CAR T cell product infusion
PALABRAS CLAVE
bcma, chronic leukemia, chronic lymphocytic leukemia (cll), hodgkin, hodgkin lymphoma, leukemia, lymphocytic, lymphoma, multiple myeloma, myeloma, non-hodgkin lymphoma, relapsed/refractory all, small lymphocytic lymphoma
